According to the Zhitong Finance App, Maiwei Bio-B (02493.HK) announced its 2026 interim results, with revenue of about 312 million yuan, up 209.06% year on year; gross profit of about 236 million yuan, up 198.67% year on year; R&D costs about 431 million yuan, up about 10% year on year; parent company owners should account for losses of about 522 million yuan, a year-on-year decrease of 5.37%.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.